Abbisko Cayman Ltd

Abbisko Therapeutics announced positive preliminary Phase 2 efficacy results for lavengratinib, also known as ABSK061, in children with achondroplasia. In the first and lowest dose cohort of 0.064mg/kg once daily, seven children aged 6 years and older who received the drug for 27 weeks achieved a mean increase of +2.4 cm/year in annualized height velocity from baseline, with a 100% responder rate. The Phase 2 ABSK061-202 study is a multicenter, open-label, dose-escalation trial evaluating the safety and efficacy of the oral FGFR2/3 inhibitor in children aged 3 to 12 years, with a planned treatment duration of 78 weeks. No serious adverse events or treatment discontinuations due to adverse events have been reported, and no FGFR1 or FGFR2-associated adverse events such as hyperphosphatemia and corneal toxicity have been observed. The study has completed preliminary safety evaluation of the first three dose cohorts, and six-month efficacy and safety results are expected by the end of 2026. Lavengratinib is the first FGFR2/3 inhibitor to enter clinical trials globally and has received Rare Pediatric Disease Designation and Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of achondroplasia.

Eli Lilly has entered a new research collaboration with Abbisko Cayman Limited and transferred commercial rights for cancer drug Verzenios in China to Innovent Biologics. The Abbisko partnership aims to expand Lilly's pipeline through external R&D, while the Verzenios agreement adjusts its commercial approach in the Chinese market. These moves highlight Lilly's strategy of using alliances to access additional science and respond to local conditions, beyond its core obesity and diabetes treatments. The outcomes will depend on research progress, regulatory decisions, and partner execution.

Abbisko Therapeutics and AstraZeneca have entered a strategic collaboration to jointly develop a combination therapy for EGFR-mutated, PD-L1 positive non-small cell lung cancer. The partnership follows China's National Medical Products Administration clearing a Phase 1/2 study on May 20, 2026, evaluating Abbisko's oral PD-L1 inhibitor lumipodlin with AstraZeneca's EGFR-targeted therapy Tagrisso. Abbisko will lead the Phase 2 trial, with both companies sharing clinical responsibilities. The combination targets a treatment gap where patients with both EGFR mutations and high PD-L1 expression derive less benefit from EGFR-TKI therapy alone.

The S&P 500 Health Care Index Sector jumped 7.48% during the week, driven by major dealmaking and legal victories. Merck KGaA agreed to acquire Bio-Techne for $73 per share in cash, valuing the deal at an enterprise value of approximately $11.3 billion, a 36% premium that sent Bio-Techne shares up more than 20%. AbbVie announced an all-cash acquisition of Apogee Therapeutics at $135.11 per share, a total equity value of about $10.9 billion, causing Apogee shares to rally 52%. The U.S. Supreme Court handed Bayer a sweeping 7-2 victory, ruling that federal pesticide regulations shield the company from state-law claims alleging Roundup should have carried a cancer warning, a decision expected to sharply reduce litigation that has cost Bayer more than $10 billion. Eli Lilly entered an R&D and licensing collaboration with China's Abbisko Therapeutics worth up to $1.9 billion, while Novartis and privately held Antares Therapeutics announced a cancer drug development deal also worth up to $1.9 billion.

Eli Lilly has entered new research and license agreements with Abbisko Therapeutics and BioArctic, adding multi-target discovery work worth up to about US$1.90 billion in milestones for Abbisko and up to US$770 million for BioArctic, alongside royalties on any future product sales. These alliances are part of Lilly's strategy to broaden its pipeline beyond its flagship GLP‑1 franchise, which continues to drive growth with Q1 2026 results and a raised full-year revenue guidance of US$82 billion to US$85 billion. While the partnerships support diversification, the key short-term catalyst remains execution and access on GLP‑1s, with the biggest risk being pricing pressure and reimbursement pushback on obesity drugs. Some analysts project around US$102 billion of revenue and US$40 billion of earnings by 2029, yet they remain cautious due to potential obesity pricing reforms and tighter safety scrutiny.

Abbisko Therapeutics has entered into a strategic research collaboration and license agreement with Eli Lilly and Company. The two companies will collaborate on the discovery and development of innovative medicines across multiple targets. Abbisko will receive an upfront payment and is eligible for development, regulatory, and commercial milestone payments totaling up to approximately US$1.9 billion, plus tiered royalties on annual net sales of resulting products. This agreement builds on a 2022 global collaboration between the firms for a novel small-molecule therapeutic.